Effects of epidermal growth factor on invasiveness through the extracellular matrix in high- and low-metastatic clones of RCT sarcoma in vitro.
We investigated the invasiveness of tumor cells through the extracellular matrix and the influence of epidermal growth factor (EGF) on tumor cell invasion using in vitro systems in high-[RCT(+)] and low-metastatic [RCT(-)] clones established from poorly differentiated murine RCT sarcoma in C3H/He mice. In the invasion assay using a filter coated with reconstituted basement membrane (Matrigel) in a Boyden chamber, RCT(+) cells were more invasive than RCT(-) cells. The attachment of RCT(+) cells to extracellular matrix components and the degradation of type IV collagen by the cells were significantly greater than with RCT(-) cells. However, there was no significant difference in the migration of cells to the extracellular matrix components between cultured RCT(+) and RCT(-) cells. These findings suggested that the different invasiveness of these clone cells was associated with the difference in the ability of attachment to and degradation of the matrix. The level of laminin receptor expression in RCT(+) cells was about four-fold that in RCT(-) cells and laminin stimulated the type IV collagenolytic activity of RCT(+) cells, suggesting that RCT(+) cell attachment to laminin via laminin receptor on the cell surface induced the production of type IV collagenase by the tumor cells. EGF did not affect the invasiveness of RCT(-) cells. In RCT(+) cells, EGF stimulated the invasiveness through Matrigel, the attachment to extracellular matrix components and the degradation of type IV collagen through high-affinity EGF receptors (EGFR), with Kd of pM order, while the migration to the matrix was not influenced by EGF. These findings suggest that the stimulatory effect of EGF on invasion is related to the acceleration of cell adhesion, and the degradative cascade of the extracellular matrix and high-affinity EGFRs play an important role in the effect of EGF on in vitro invasiveness in this tumor.
Yudoh
K
K
Department of Orthopaedic Surgery, Toyama Medical and Pharmaceutical University, Faculty of Medicine.
Matsui
H
H
Kanamori
M
M
Maeda
A
A
Ohmori
K
K
Tsuji
H
H
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D004338:Drug Combinations; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005109:Extracellular Matrix; D005353:Fibronectins / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D009361:Neoplasm Invasiveness; D011509:Proteoglycans; D012513:Sarcoma, Experimental / Q000737:chemistry / Q000473:pathology
D004338:Drug Combinations; D005353:Fibronectins; D007797:Laminin; D011509:Proteoglycans; C059485:matrigel; D004815:Epidermal Growth Factor; D003094:Collagen